Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof

Compound of the formula (I)

• in which
• R2 represents a hydrogen or fluorine atom, a hydroxyl, cyano, trifluoromethyl, C1-6 alkyl or C1-6 alkoxy group or a group NR8R9;
• n represents an integer 1, 2 or 3 and m represents an integer 1 or 2;
• A represents a covalent bond or a C1-8 alkylene group;
• R1 represents a group R5 which is optionally substituted by one or more groups R6 and/or R7;
• R5 represents a group selected from a phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, naphthalenyl, quinolinyl, isoquinolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, cinnolinyl or naphthyridinyl;
• R6 represents a halogen atom, a cyano, —CH2CN, nitro, hydroxyl, C1-6 alkyl, C1-6 alkoxy, C1-6 thioalkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C1-6 halothioalkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-3 alkylene or C3-7 cycloalkyl-C1-3 alkylene-O— group, or a group NR8R9, NR8COR9, NR8CO2R9, NR8SO2R9, NR8SO2NR8R9, COR8, CO2R8, CONR8R9, SO2R8, SO2NR8R9 or —O—(C1-3-alkylene)-O—;
• R7 represents a group selected from a furanyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazole, thiadiazole, phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazine, naphthalenyl, quinolinyl, isoquinolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, imidazopyrimidinyl, thienopyrimidinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, indolyl, isoindolyl, indazolyl, pyrrolopyridinyl, furopyridinyl, thienopyridinyl, imidazopyridinyl, pyrazolopyridinyl, oxazolopyridinyl, isoxazolopyridinyl, thiazolopyridinyl, phenyloxy, benzyloxy or pyrimidinoxy, the group or groups R7 being able to be substituted by one or more groups R6 which are identical or different from one another;
• R3 represents a hydrogen or fluorine atom, a C1-6 alkyl group or a trifluoromethyl group;
• R4 represents a thiazole which is optionally substituted by one or more substituents selected from a halogen atom, a C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-3 alkylene, C1-6 haloalkoxy, cyano, NR8R9, NR8COR9, NR8CO2R9, NR8SO2R9, NR8SO2NR8R9, COR8, CO2R8, CONR8R9, SO2R8, SO2NR8R9, —O—(C1-3-alkylene)-O—, phenyl, phenyloxy, benzyloxy, pyridinyl, pyrazinyl, pyridazinyl, triazinyl or pyrimidinyl group, it being possible for the phenyl, phenyloxy, pyridinyl, pyrazinyl, pyridazinyl, triazinyl and pyrimidinyl groups to be substituted by one or more substituents selected from a halogen atom and a cyano, nitro, C1-6 alkyl, C1-6 alkoxy, C1-6 thioalkyl, C1-6 haloalkyl, C1-6 haloalkoxy, Cr-6 halothioalkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-3 alkylene group;
• R8 and R9 represent independently of one another a hydrogen atom or a C1-6 alkyl group, or form, with the atom or atoms bearing them,
• in the case of NR8R9, a ring selected from azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine, azepine, oxazepine or piperazine ring, this ring being optionally substituted by a C1-6 alkyl or benzyl group;
• in the case of NR8COR9, a lactam ring;
• in the case of NR8CO2R9, an oxazolidinone, oxazinone or oxazepinone ring;
• in the case of NR8SO2R9, a sultam ring;
• in the case of NR8SO2NR8R9, a thiazolidine dioxide or thiadiazinane dioxide ring;
• in the form of the base or an addition salt with an acid;
• the following compounds being excluded:
• methyl 2-(3-{[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxycarbonylamino}piperidin-1-yl)benzoate;
• 2-(3-{[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxycarbonylamino}piperidin-1-yl)benzoic acid;
• methyl 3-(3-{[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxycarbonylamino}piperidin-1-yl)benzoate;
• 3-(3-{[2-(4-chlorophenyl)-4-methylthiazol-5-yl]methoxycarbonylamino}piperidin-1-yl)benzoic acid.